First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies. (December 2016) - Postel-Vinay, S.; Herbschleb, K.; Massard, C.; Woodcock, V.; Ocker, M.; Wilkinson, G.; Walter, A.; Ewerton, F.; Poelman, M.; Middleton, M.; Soria, J.C.